Trial Profile
An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2022
Price :
$35
*
At a glance
- Drugs Copper 64 DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use; Registrational
- Sponsors RadioMedix
- 19 Jul 2019 Status changed from recruiting to completed.
- 25 Sep 2018 New trial record